undamentalytics Newsletter
Sign in

Ideaya Biosciences, Inc. balance sheet

At the end of fiscal 2025, Ideaya Biosciences, Inc. had total assets of $1.11bn, total liabilities of $86.4m and shareholders' equity of $1.02bn. It held $113m in cash against $0 of debt: net cash of $113m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents3472926915784113273
Receivables—21000——
Total current assets102289251370533690667864
Total assets1132983813886491,1241,1091,310
Accounts payable11247151831
Deferred revenue (current)—28299————
Total current liabilities739453227465983
Total debt00000000
Total liabilities131008039286586111
Shareholders' equity1001983023496211,0591,0231,199
Net debt (negative = net cash)−34−72−92−69−157−84−113−273
Shares outstanding20m30m39m48m65m87m88m96m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: IDYA vs PBYIANAB vs IDYAIDYA vs RYTMAKBA vs IDYA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Ideaya Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ideaya Biosciences, Inc.